Zacks: Brokerages Expect Design Therapeutics, Inc. (NASDAQ:DSGN) Will Announce Earnings of -$0.22 Per Share

Wall Street analysts expect Design Therapeutics, Inc. (NASDAQ:DSGN) to announce earnings of ($0.22) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Design Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.22). The company is scheduled to report its next earnings report on Tuesday, February 8th.

On average, analysts expect that Design Therapeutics will report full year earnings of ($0.83) per share for the current financial year, with EPS estimates ranging from ($0.86) to ($0.80). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.04) per share, with EPS estimates ranging from ($1.31) to ($0.76). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Design Therapeutics.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Tuesday, November 9th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.07).

Separately, Zacks Investment Research downgraded Design Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 11th.

Shares of DSGN stock traded up $0.74 during trading hours on Friday, reaching $15.85. The company’s stock had a trading volume of 81,911 shares, compared to its average volume of 80,351. The firm’s 50 day simple moving average is $18.44 and its 200-day simple moving average is $17.12. Design Therapeutics has a fifty-two week low of $12.52 and a fifty-two week high of $50.50.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. boosted its holdings in shares of Design Therapeutics by 4.7% during the 3rd quarter. Citigroup Inc. now owns 24,808 shares of the company’s stock valued at $364,000 after acquiring an additional 1,118 shares in the last quarter. Rock Springs Capital Management LP boosted its holdings in shares of Design Therapeutics by 0.6% during the 3rd quarter. Rock Springs Capital Management LP now owns 334,050 shares of the company’s stock valued at $4,907,000 after acquiring an additional 2,000 shares in the last quarter. Piper Sandler & CO. acquired a new stake in shares of Design Therapeutics during the 3rd quarter valued at $37,000. Bank of New York Mellon Corp boosted its holdings in shares of Design Therapeutics by 8.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,476 shares of the company’s stock valued at $536,000 after acquiring an additional 2,979 shares in the last quarter. Finally, Pinz Capital Management LP acquired a new stake in shares of Design Therapeutics during the 2nd quarter valued at $86,000. 50.45% of the stock is currently owned by institutional investors.

About Design Therapeutics

Design Therapeutics, Inc develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy.

Read More: Options Trading – Understanding Strike Price

Get a free copy of the Zacks research report on Design Therapeutics (DSGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.